{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:12:36Z","timestamp":1790485956443,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-006860"],"award-info":[{"award-number":["INV-006860"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV endpoint-driven clinical trials in Africa enroll women who are at heightened risk of acquiring HIV. In 2017, the South African Medical Research Council recommended the provision of oral pre-exposure prophylaxis (PrEP) in HIV prevention trials, at which time the Evidence for Contraceptive Options and HIV Outcomes trial was ongoing and began to provide PrEP on-site at some trial sites. We interviewed 132 women who initiated PrEP on-site at the Durban, South Africa trial site to explore PrEP use, and conducted phone-based interviews 4\u20136 months post-trial exit to explore post-trial PrEP access. PrEP uptake was high (42.6%). Among women initiating PrEP on-site, 87.9% felt at risk of acquiring HIV. Most women (&gt;\u200990%) heard of PrEP for the first time from study staff and three-quarters who initiated PrEP on-site continued at trial-exit. PrEP use declined post-trial exit with more than 50% of women discontinuing PrEP, and barriers relating to access emerged.<\/jats:p>","DOI":"10.1007\/s10461-020-03072-0","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T18:02:54Z","timestamp":1603735374000},"page":"1112-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-8123","authenticated-orcid":false,"given":"Ivana","family":"Beesham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Heffron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mags","family":"Beksinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila E.","family":"Mansoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"3072_CR1","unstructured":"Avert. HIV and AIDS in South Africa. https:\/\/www.avert.org\/professionals\/hiv-around-world\/sub-saharan-africa\/south-africa (2020). Accessed 2 Mar 2020."},{"key":"3072_CR2","unstructured":"UNAIDS. Country: South Africa. https:\/\/www.unaids.org\/en\/regionscountries\/countries\/southafrica (2020). Accessed 2 Mar 2020."},{"key":"3072_CR3","unstructured":"World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. https:\/\/www.who.int\/hiv\/pub\/guidelines\/earlyrelease-arv\/en\/ (2015). Accessed 2 Mar 2020."},{"key":"3072_CR4","unstructured":"South Africa National Department of Health. Guidelines for expanding combination prevention and treatment options for sex workers: oral pre-exposure prophylaxis (PrEP) and test and treat (T&T). https:\/\/www.nicd.ac.za\/assets\/files\/PrEP and TT guidelines\u2014final draft\u201411 May 2016.pdf (2020). Accessed 2 Mar 2020."},{"key":"3072_CR5","unstructured":"Pillay Y. Challenges of South Africa\u2019s sex worker PrEP programme: lessons learned, moving towards to other key populations. In: 22nd International AIDS Conference Amsterdam, The Netherlands; 2018"},{"key":"3072_CR6","unstructured":"AVAC. Ongoing and planned PrEP open label, demonstration and implementation projects, August 2018, pp. 1\u20135. https:\/\/www.avac.org\/sites\/default\/files\/resource-files\/ongoing_planned_oralPrEP_studies_aug2018.pdf (2018). Accessed 28 Feb 2020."},{"key":"3072_CR7","unstructured":"UNAIDS\/WHO. Ethical considerations in biomedical HIV prevention trials [Additional guidance point added in 2012]. https:\/\/www.unaids.org (2019). Accessed 23 Aug 2019."},{"key":"3072_CR8","unstructured":"South Africa National Department of Health. National policy on HIV pre-exposure prophylaxis (PrEP) and test and treat (T&T) final draft\u20145 May 2016 Updated\u20148 December 2016. https:\/\/sahivsoc.org\/Files\/PREP%20and%20TT%20Policy%20-%20Final%20Draft%20-%205%20May%202016%20(HIV%20news).pdf (2020). Accessed 15 Sept 2020."},{"key":"3072_CR9","unstructured":"HIV Prevention Trials Network. HIV prevention trials network ethics guidance for research. https:\/\/www.hptn.org\/sites\/default\/files\/2016-05\/HPTNEthicsGuidanceV10Jun2009_0.pdf (2009). Accessed 2 Mar 2020."},{"key":"3072_CR10","unstructured":"South African Medical Research Council. Executive summary of the summit on the standard of care in clinical trials in low-middle income settings. https:\/\/www.samrc.ac.za\/sites\/default\/files\/publications\/2019-01-17\/ExecSumSummitStandardCare.pdf (2017). Accesssed 2 Mar 2020."},{"key":"3072_CR11","unstructured":"Hannah S, Hubbard M, Salzwedel J, Sugarman J, Wakefield S. HIV research in the Era of PrEP: the implications of TDF\/FTC for biomedical prevention trials. www.treatmentactiongroup.org (2017). Accessed 27 Aug 2019."},{"issue":"10195","key":"3072_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(19)31288-7","volume":"394","author":"Evidence for contraceptive options and hiv outcomes (ECHO) Trial Consortium","year":"2019","unstructured":"Evidence for contraceptive options and hiv outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303\u201313.","journal-title":"Lancet"},{"key":"3072_CR13","unstructured":"Palanee-Phillips T, Baeten J, Heller K et al. High HIV incidence among young women in South Africa: data from the ECHO trial. In: 10th IAS Conference HIV Science Mexico City, Mexico; 2019"},{"issue":"5","key":"3072_CR14","doi-asserted-by":"publisher","first-page":"e25491","DOI":"10.1002\/jia2.25491","volume":"23","author":"I Beesham","year":"2020","unstructured":"Beesham I, Welch JD, Heffron R, et al. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. J Int AIDS Soc. 2020;23(5):e25491. https:\/\/doi.org\/10.1002\/jia2.25491.","journal-title":"J Int AIDS Soc."},{"key":"3072_CR15","unstructured":"University of Witwatersrand. REDCap\u00ae. https:\/\/redcap.core.wits.ac.za\/redcap\/ (2020). Accessed 2 Mar 2020."},{"issue":"S4","key":"3072_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/jia2.25298","volume":"22","author":"CL Celum","year":"2019","unstructured":"Celum CL, Delany-Moretlwe S, Baeten JM, et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(S4):23\u20139.","journal-title":"J Int AIDS Soc."},{"issue":"5","key":"3072_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1202614.","journal-title":"N Engl J Med."},{"issue":"6","key":"3072_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1402269.","journal-title":"N Engl J Med."},{"key":"3072_CR19","unstructured":"Celum C. PrEP use in young African women in HPTN 082: effect of drug level feedback. In: 10th IAS Conference HIV Science Mexico City, Mexico; 2019"},{"key":"3072_CR20","unstructured":"Grey GE. Presentation of HVTN702 Study Data. In: Conference on retroviruses and opportunitistic infections (CROI). Virtual; 2020."},{"issue":"7","key":"3072_CR21","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1016\/S2352-3018(19)30133-X","volume":"6","author":"H Janes","year":"2006","unstructured":"Janes H, Donnell D, Gilbert PB, Brown ER, Nason M. Viewpoint taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. Lancet HIV. 2006;6(7):e475\u201382. https:\/\/doi.org\/10.1016\/S2352-3018(19)30133-X.","journal-title":"Lancet HIV"},{"issue":"3","key":"3072_CR22","doi-asserted-by":"publisher","first-page":"e25463","DOI":"10.1002\/jia2.25463","volume":"23","author":"J Velloza","year":"2020","unstructured":"Velloza J, Khoza N, Scorgie F, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463.","journal-title":"J Int AIDS Soc."},{"key":"3072_CR23","unstructured":"Pillay D, Stankevitz K, Murire M, et al. Factors influencing initiation, continuation & discontinuation of oral PrEP at selected facilities in South Africa. https:\/\/www.prepwatch.org\/wp-content\/uploads\/2019\/01\/DPillay_SACliniciansSocietyConf_Oct18.pdf (2020). Accessed 8 Apr 2020."},{"issue":"8","key":"3072_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jia2.25370","volume":"22","author":"MN Pyra","year":"2019","unstructured":"Pyra MN, Haberer JE, Hasen N, Reed J, Mugo NR, Baeten JM. Global implementation of PrEP for HIV prevention: setting expectations for impact. J Int AIDS Soc. 2019;22(8):1\u20137.","journal-title":"J Int AIDS Soc."},{"issue":"2","key":"3072_CR25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1371\/journal.pone.0089118","volume":"9","author":"A Van Der Straten","year":"2014","unstructured":"Van Der Straten A, Stadler J, Montgomery E, et al. Women\u2019s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):21.","journal-title":"PLoS ONE"},{"key":"3072_CR26","unstructured":"Buchbinder SP. Advances in HIV Prevention. In: Conference on Retroviruses and Opportunitistic Infections (CROI). Virtual; 2020"},{"key":"3072_CR27","first-page":"18","volume-title":"Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Current opinion in HIV and AIDS","author":"KA Thomson","year":"2016","unstructured":"Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Current opinion in HIV and AIDS, vol. 11. Philadelphia: Lippincott Williams and Wilkins; 2016. p. 18\u201326."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-020-03072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-020-03072-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-020-03072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:29:46Z","timestamp":1635208186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-020-03072-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3072"],"URL":"https:\/\/doi.org\/10.1007\/s10461-020-03072-0","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"assertion":[{"value":"21 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}